URGN
UroGen Pharma Ltd
Halal Rating :
Last Price
$10.30
Last updated:
Market Cap
-
7D Change
1.18%
1 Year Change
-31.47%
Company Overview
Industries
Exchange
Next Earnings Date
UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing innovative solutions to treat urothelial and specialty cancers. Their lead product, Jelmyto® (mitomycin) for pyelocalyceal solution, is the first and only FDA-approved therapy for low-grade upper tract urothelial cancer (LG-UTUC). The company utilizes its proprietary RTGel™ technology platform to develop sustained-release, novel formulations of existing drugs.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $25.2m | $45.47m | - | $2.72m | 0.00% | 5.98% |
| June 30, 2024 | $21.85m | $51.15m | - | $3.46m | 0.00% | 6.77% |
| March 31, 2024 | $18.78m | $46.97m | - | $2.45m | 0.00% | 5.21% |
Company Impact
Help us evaluate UroGen Pharma Ltd's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.